You are here: Industry Insights > Lundbeck

News List

Lundbeck trims full-year sales outlook as Northera generics bite firstwordpharma
August 19, 2021
CEO Deborah Dunsire said growth of Lundbeck's strategic brands in the second-quarter has been accelerating post-pandemic, recording double-digit gains again "as we begin to see more normalised interaction between physicians and patients."
Denovo Biopharma In-Licenses Late-Stage Alzheimer's Disease Asset from Lundbeck firstwordpharma
July 02, 2021
Denovo Biopharma LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced it has licensed global rights for idalopirdine from H. Lundbeck A/S.
Verantos and Lundbeck Partner for Migraine Care Implementing Advanced Real-World Evidence americanpharmaceuticalreview
May 24, 2021
Verantos, the market leader in high-validity real-world evidence (RWE) generation, announced a partnership with Lundbeck, a global biopharmaceutical company specializing in brain diseases.
Behind the curtain on Lundbeck's Alder buy fiercepharma
September 26, 2019
Aiming to avoid jeopardizing the licensing talks, the pair decided to run the two negotiations in parallel.
Takeda and Lundbeck’s Trintellix approved in Japan for depression pharmaceutical-technology
September 25, 2019
Takeda has announced that its drug Trintellix (vortioxetine) has been approved by the Japanese Ministry of Health, Labour and Welfare for the treatment of depression and depressed state.
Advicenne Signs Manufacturing Agreement with Elaiapharm Lundbeck contractpharma
September 16, 2019
French CDMO to produce Advicenne’s lead candidate ADV7103 through long-term manufacturing supply agreement.
Lundbeck to purchase Abide Therapeutics in $400m deal pharmaceutical-technology
May 08, 2019
Danish pharmaceutical company Lundbeck has signed a $400m definitive agreement to acquire US-based Abide Therapeutics.
Jazz, Alexion and Lundbeck to pay $122m to settle kickback probe pharmaceutical-technology
April 09, 2019
Drugmakers Jazz Pharmaceuticals, Lundbeck and Alexion Pharmaceuticals have agreed to pay a total of $122.6m to settle allegations of paying kickbacks via copay assistance foundations.
Health Canada Approves Otsuka and Lundbeck's REXULTI (brexpiprazole) as Adjunctive Treatment of Major Depressive Disorder firstwordpharma
February 23, 2019
"Brexpiprazole, is a new option for patients with MDD who require augmentation therapy. Its unique mechanism of action and potential benefits will be a new source of optimism for patients suffering from Depression" said Dr. Diane McIntosh.
Lundbeck craters as resistant schizophrenia drug fails phase III pharmaphorum
December 19, 2018
Danish drugmaker Lundbeck saw more than a quarter of the value wiped off its shares yesterday after its top pipeline prospect, a drug for schizophrenia, missed the mark in a phase III trial.....

Previous page 1 2 Next page